117 related articles for article (PubMed ID: 33129591)
1. Development of prohibitin ligands against osteoporosis.
Tabti R; Lamoureux F; Charrier C; Ory B; Heymann D; Bentouhami E; Désaubry L
Eur J Med Chem; 2021 Jan; 210():112961. PubMed ID: 33129591
[TBL] [Abstract][Full Text] [Related]
2. Prohibitin ligands: a growing armamentarium to tackle cancers, osteoporosis, inflammatory, cardiac and neurological diseases.
Wang D; Tabti R; Elderwish S; Abou-Hamdan H; Djehal A; Yu P; Yurugi H; Rajalingam K; Nebigil CG; Désaubry L
Cell Mol Life Sci; 2020 Sep; 77(18):3525-3546. PubMed ID: 32062751
[TBL] [Abstract][Full Text] [Related]
3. Discovery of 3,3'-pyrrolidinyl-spirooxindoles as cardioprotectant prohibitin ligands.
Elderwish S; Audebrand A; Nebigil CG; Désaubry L
Eur J Med Chem; 2020 Jan; 186():111859. PubMed ID: 31735574
[TBL] [Abstract][Full Text] [Related]
4. Strontium substitution in apatitic CaP cements effectively attenuates osteoclastic resorption but does not inhibit osteoclastogenesis.
Schumacher M; Wagner AS; Kokesch-Himmelreich J; Bernhardt A; Rohnke M; Wenisch S; Gelinsky M
Acta Biomater; 2016 Jun; 37():184-94. PubMed ID: 27084107
[TBL] [Abstract][Full Text] [Related]
5. Prohibitin ligands in cell death and survival: mode of action and therapeutic potential.
Thuaud F; Ribeiro N; Nebigil CG; Désaubry L
Chem Biol; 2013 Mar; 20(3):316-31. PubMed ID: 23521790
[TBL] [Abstract][Full Text] [Related]
6. Development of fluorizoline analogues as prohibitin ligands that modulate C-RAF signaling, p21 expression and melanogenesis.
Chouha N; Abou-Hamdan H; Yurugi H; Yoshii R; Ii H; Najem A; Ghanem GE; Nakata S; Rajalingam K; Peng Y; Wang D; Nebigil CG; Désaubry L
Eur J Med Chem; 2022 Nov; 242():114635. PubMed ID: 35988448
[TBL] [Abstract][Full Text] [Related]
7. Gastrodin inhibits osteoclastogenesis via down-regulating the NFATc1 signaling pathway and stimulates osseointegration in vitro.
Zhou F; Shen Y; Liu B; Chen X; Wan L; Peng D
Biochem Biophys Res Commun; 2017 Mar; 484(4):820-826. PubMed ID: 28161640
[TBL] [Abstract][Full Text] [Related]
8. Chemical affinity matrix-based identification of prohibitin as a binding protein to anti-resorptive sulfonyl amidine compounds.
Chang SY; Bae SJ; Lee MY; Baek SH; Chang S; Kim SH
Bioorg Med Chem Lett; 2011 Jan; 21(2):727-9. PubMed ID: 21195613
[TBL] [Abstract][Full Text] [Related]
9. Cumambrin A prevents OVX-induced osteoporosis
Zhou L; Liu Q; Hong G; Song F; Zhao J; Yuan J; Xu J; Tan RX; Tickner J; Gu Q; Xu J
FASEB J; 2019 Jun; 33(6):6726-6735. PubMed ID: 30807230
[TBL] [Abstract][Full Text] [Related]
10. Increased levels of sodium chloride directly increase osteoclastic differentiation and resorption in mice and men.
Wu L; Luthringer BJC; Feyerabend F; Zhang Z; Machens HG; Maeda M; Taipaleenmäki H; Hesse E; Willumeit-Römer R; Schilling AF
Osteoporos Int; 2017 Nov; 28(11):3215-3228. PubMed ID: 28849275
[TBL] [Abstract][Full Text] [Related]
11. Osteoclastogenic capacity of peripheral blood mononuclear cells is not different between women with and without osteoporosis.
Koek WNH; van der Eerden BCJ; Alves RDAM; van Driel M; Schreuders-Koedam M; Zillikens MC; van Leeuwen JPTM
Bone; 2017 Feb; 95():108-114. PubMed ID: 27845263
[TBL] [Abstract][Full Text] [Related]
12. A novel anti-osteoporotic agent that protects against postmenopausal bone loss by regulating bone formation and bone resorption.
Yang YT; Meng JH; Hu B; Ma CY; Zhao CC; Teng WS; Hong JQ; Li SH; Jiang GY; Wang C; Zhou CH; Yan SG
Life Sci; 2018 Sep; 209():409-419. PubMed ID: 30096387
[TBL] [Abstract][Full Text] [Related]
13. Artesunate inhibits RANKL-induced osteoclastogenesis and bone resorption in vitro and prevents LPS-induced bone loss in vivo.
Wei CM; Liu Q; Song FM; Lin XX; Su YJ; Xu J; Huang L; Zong SH; Zhao JM
J Cell Physiol; 2018 Jan; 233(1):476-485. PubMed ID: 28294321
[TBL] [Abstract][Full Text] [Related]
14. Novel 2,7-Diazaspiro[4,4]nonane Derivatives to Inhibit Mouse and Human Osteoclast Activities and Prevent Bone Loss in Ovariectomized Mice without Affecting Bone Formation.
Mounier L; Morel A; Ferrandez Y; Morko J; Vääräniemi J; Gilardone M; Roche D; Cherfils J; Blangy A
J Med Chem; 2020 Nov; 63(22):13680-13694. PubMed ID: 33175535
[TBL] [Abstract][Full Text] [Related]
15. Tomatidine suppresses osteoclastogenesis and mitigates estrogen deficiency-induced bone mass loss by modulating TRAF6-mediated signaling.
Hu B; Sun X; Yang Y; Ying Z; Meng J; Zhou C; Jiang G; Li S; Wu F; Zhao X; Zhu H; Wu H; Cai X; Shi Z; Yan S
FASEB J; 2019 Feb; 33(2):2574-2586. PubMed ID: 30285579
[TBL] [Abstract][Full Text] [Related]
16. Proanthocyanidins inhibit osteoclast formation and function by inhibiting the NF-κB and JNK signaling pathways during osteoporosis treatment.
Zhu W; Yin Z; Zhang Q; Guo S; Shen Y; Liu T; Liu B; Wan L; Li S; Chen X; Ouyang Z; Peng D
Biochem Biophys Res Commun; 2019 Jan; 509(1):294-300. PubMed ID: 30583865
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous delivery of BMP-2 factor and anti-osteoporotic drugs using hyaluronan-assembled nanocomposite for synergistic regulation on the behaviors of osteoblasts and osteoclasts in vitro.
Zhang Y; Hu Y; Luo Z; Shen X; Mu C; Cai K
J Biomater Sci Polym Ed; 2015; 26(5):290-310. PubMed ID: 25585099
[TBL] [Abstract][Full Text] [Related]
18. Loureirin B suppresses RANKL-induced osteoclastogenesis and ovariectomized osteoporosis via attenuating NFATc1 and ROS activities.
Liu Y; Wang C; Wang G; Sun Y; Deng Z; Chen L; Chen K; Tickner J; Kenny J; Song D; Zhang Q; Wang H; Chen Z; Zhou C; He W; Xu J
Theranostics; 2019; 9(16):4648-4662. PubMed ID: 31367247
[No Abstract] [Full Text] [Related]
19. FL3, a Synthetic Flavagline and Ligand of Prohibitins, Protects Cardiomyocytes via STAT3 from Doxorubicin Toxicity.
Qureshi R; Yildirim O; Gasser A; Basmadjian C; Zhao Q; Wilmet JP; Désaubry L; Nebigil CG
PLoS One; 2015; 10(11):e0141826. PubMed ID: 26536361
[TBL] [Abstract][Full Text] [Related]
20. The Dimension of Titania Nanotubes Influences Implant Success for Osteoclastogenesis and Osteogenesis Patients.
Li Y; Li F; Zhang C; Gao B; Tan P; Mi B; Zhang Y; Cheng H; Liao H; Huo K; Xiong W
J Nanosci Nanotechnol; 2015 Jun; 15(6):4136-42. PubMed ID: 26369022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
